TY - JOUR
T1 - Personalized medicine in non-small cell lung cancer
T2 - a review from a pharmacogenomics perspective
AU - Jiang, Wenxiao
AU - Cai, Guiqing
AU - Hu, Peter C.
AU - Wang, Yue
N1 - Publisher Copyright:
© 2018 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences
PY - 2018/7
Y1 - 2018/7
N2 - Non-small cell lung cancer is a prevalent and rapidly-expanding challenge to modern medicine. While generalized medicine with traditional chemotherapy yielded comparatively poor response rates and treatment results, the cornerstone of personalized medicine using genetic profiling to direct treatment has exalted the successes seen in the field and raised the standard for patient treatment in lung and other cancers. Here, we discuss the current state and advances in the field of personalized medicine for lung cancer, reviewing several of the mutation-targeting strategies that are approved for clinical use and how they are guided by patient genetic information. These classes include inhibitors of tyrosine kinase (TKI), anaplastic lymphoma kinase (ALK), and monoclonal antibodies. Selecting from these treatment plans and determining the optimal dosage requires in-depth genetic guidance with consideration towards not only the underlying target genes but also other factors such as individual metabolic capability and presence of resistance-conferring mutations both directly on the target gene and along its cascade(s). Finally, we provide our viewpoints on the future of personalized medicine in lung cancer, including target-based drug combination, mutation-guided drug design and the necessity for data of population genetics, to provide rough guidance on treating patients who are unable to get genetic testing.
AB - Non-small cell lung cancer is a prevalent and rapidly-expanding challenge to modern medicine. While generalized medicine with traditional chemotherapy yielded comparatively poor response rates and treatment results, the cornerstone of personalized medicine using genetic profiling to direct treatment has exalted the successes seen in the field and raised the standard for patient treatment in lung and other cancers. Here, we discuss the current state and advances in the field of personalized medicine for lung cancer, reviewing several of the mutation-targeting strategies that are approved for clinical use and how they are guided by patient genetic information. These classes include inhibitors of tyrosine kinase (TKI), anaplastic lymphoma kinase (ALK), and monoclonal antibodies. Selecting from these treatment plans and determining the optimal dosage requires in-depth genetic guidance with consideration towards not only the underlying target genes but also other factors such as individual metabolic capability and presence of resistance-conferring mutations both directly on the target gene and along its cascade(s). Finally, we provide our viewpoints on the future of personalized medicine in lung cancer, including target-based drug combination, mutation-guided drug design and the necessity for data of population genetics, to provide rough guidance on treating patients who are unable to get genetic testing.
KW - Anaplastic lymphoma kinase
KW - Inhibitor
KW - Monoclonal antibody
KW - Non-small cell lung cancer
KW - Personalized medicine
KW - Pharmacogenomics
KW - Tyrosine kinase
UR - http://www.scopus.com/inward/record.url?scp=85047096005&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85047096005&partnerID=8YFLogxK
U2 - 10.1016/j.apsb.2018.04.005
DO - 10.1016/j.apsb.2018.04.005
M3 - Review article
C2 - 30109178
AN - SCOPUS:85047096005
SN - 2211-3835
VL - 8
SP - 530
EP - 538
JO - Acta Pharmaceutica Sinica B
JF - Acta Pharmaceutica Sinica B
IS - 4
ER -